DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Actinic Keratosis market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Actinic Keratosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Actinic Keratosis: An Overview
Actinic keratosis (AK) is a chronic and prevalent disease affecting areas of sun-exposed skin where visible and subclinical, non-visible lesions coexist. This area of sun-damaged skin is prone to developing further visible AK lesions and sun-related skin cancer and is known as ‘field cancerization’.
AK lesions are represented as small scaly patches that can be flat or slightly raised. Their colour can range from one’s skin tone to a reddish-brown colour. They differ in size from 3 mm to 10 mm across and may gradually enlarge. AK lesions appear on areas that are most commonly exposed to the sun, such as the face, scalp, shoulders, neck, back of the hands and forearms, etc.
The Actinic Keratosis market is available with several treatment options. The prevalence of Actinic Keratosis is increasing widely. Factors leading to increased prevalence include cumulative ultraviolet radiation exposure, increasing age and childhood sun exposure, male working more outdoors and resident of the population in latitudes that is close to equators.
Actinic Keratosis Market Key Facts
-
Actinic Keratosis is more prevalent among the male than the female population. DelveInsight estimates that the male-to-female ratios of Actinic Keratosis patients differ among various countries, but a male excess is a consistent finding among all countries except Italy.
-
As per the estimation by DelveInsight’s analysts, the United States had the highest prevalence of Actinic Keratosis with approximately 66 million prevalent population in 2020.
-
Among the EU5 countries, Germany had the highest prevalent population with approximately 8 million cases followed by the United Kingdom with a prevalent population of approximately 5 million in 2020. On the other hand, Japan has the lowest prevalent population with approximately 7 lakh cases in 2020.
-
The Actinic Keratosis therapeutics market is segmented widely into three main therapies that include lesion-directed destructive therapies, field-directed topical therapies and photodynamic therapies.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Actinic Keratosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Actinic Keratosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Actinic Keratosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Actinic Keratosis Epidemiology Segmentation –
-
Total Prevalent Population of Actinic Keratosis
-
Gender-Specific Prevalent Population of Actinic Keratosis
-
Total Diagnosed Prevalent Population of Actinic Keratosis
Actinic Keratosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Actinic Keratosis market or expected to get launched during the study period. The analysis covers the Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Actinic Keratosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Actinic Keratosis Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/actinic-keratosis-market
Actinic Keratosis Therapeutics Analysis
Globally, several major players are working toward developing new topical therapies for Actinic Keratosis. There are many promising candidates in the late stage of clinical development for the treatment of Actinic Keratosis, which are expected to impact the Actinic Keratosis therapeutics market and treatment scenario positively.
Some of the Key Companies in the Actinic Keratosis Therapeutics Market Include:
Athenex, Vidac Pharma, DFB Soria, LEO Pharma, Almirall S.A., Biofrontera, Galderma, Almirall, DUSA Pharmaceuticals, Aqua Pharmaceuticals, Bausch Health Companies, Sandoz Pharmaceuticals, Photonamic GmbH & Co. KG, and many others
Actinic Keratosis Therapies covered in the report include:
Aldara, Zyclara, Solaraze, Efudex, Carac, Picato, Actikerell, Fluoroplex, Ameluz, Metvixia, Alacare, Levulan Kerastick, Klisyri (tirbanibulin), VDA-1102, SOR 007, and many more.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
https://www.delveinsight.com/sample-request/actinic-keratosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Actinic Keratosis Competitive Intelligence Analysis
4. Actinic Keratosis Market Overview at a Glance
5. Actinic Keratosis Disease Background and Overview
6. Actinic Keratosis Patient Journey
7. Actinic Keratosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Actinic Keratosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Actinic Keratosis Unmet Needs
10. Key Endpoints of Actinic Keratosis Treatment
11. Actinic Keratosis Marketed Products
12. Actinic Keratosis Emerging Drugs and Latest Therapeutic Advances
13. Actinic Keratosis Seven Major Market Analysis
14. Attribute Analysis
15. Actinic Keratosis Market Outlook (In US, EU5, and Japan)
16. Actinic Keratosis Access and Reimbursement Overview
17. KOL Views on the Actinic Keratosis Market
18. Actinic Keratosis Market Drivers
19. Actinic Keratosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/actinic-keratosis-market
Other Trending Healthcare Reports By DelveInsight
Actinic Keratosis Pipeline Insight
“Actinic keratosis Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Actinic keratosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/